Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Schrodinger, Inc.SDGR · Entity 4667 | Director · President & CEO | April 16, 2026 | April 17, 2026 |
| Structure Therapeutics Inc.GPCR · Entity 1222 | Director | February 07, 2023 | February 10, 2023 |
| Vir Biotechnology, Inc.VIR · Entity 4522 | Director | May 27, 2026 | May 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Schrodinger, Inc.
Report date April 16, 2026 · Filed April 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 373,824 |
Reported balance
After 2026-04-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-16 · Exercise / conversion · Acquired 43,000 · Balance 373,824 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 330,824 |
Reported balance
After 2026-04-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-04-16 · Sale · Disposed 43,000 · Balance 330,824 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.80 to $12.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote(2) of this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 373,824 |
Reported balance
After 2026-04-17 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-04-17 · Exercise / conversion · Acquired 43,000 · Balance 373,824 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 330,824 |
Reported balance
After 2026-04-17 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-04-17 · Sale · Disposed 43,000 · Balance 330,824 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2025. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.66 to $12.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote(3) of this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 405,351 |
Reported balance
After 2026-04-17 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-04-17 · Exercise / conversion · Acquired 74,527 · Balance 405,351 F4: Includes 132,634 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.07 · Expires 2026-05-10 | Direct | 117,527 |
Reported balance
After 2026-04-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-04-16 · Exercise / conversion · Disposed 43,000 · Balance 117,527 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2025. F5: The option was granted on May 11, 2016 and is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.07 · Expires 2026-05-10 | Direct | 74,527 |
Reported balance
After 2026-04-17 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-04-17 · Exercise / conversion · Disposed 43,000 · Balance 74,527 F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2025. F5: The option was granted on May 11, 2016 and is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.07 · Expires 2026-05-10 | Direct | 0 |
Reported balance
After 2026-04-17 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-04-17 · Exercise / conversion · Disposed 74,527 · Balance 0 F5: The option was granted on May 11, 2016 and is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.80 to $12.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote(2) of this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.66 to $12.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote(3) of this Form 4.
F4: Includes 132,634 unvested RSUs.
F5: The option was granted on May 11, 2016 and is fully vested.
Structure Therapeutics Inc.
Report date February 07, 2023 · Filed February 10, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Schrodinger, Inc. | 3,260,495 |
Reported balance
After 2023-02-07 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-02-07 · Conversion · Acquired 642,245 · Balance 3,260,495 F1: All outstanding Preferred Shares automatically converted into Ordinary Shares immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one Ordinary Share for each one Preferred Share, based on the conversion price currently in effect. The Preferred Shares have no expiration date. F2: The Reporting Person is President, Chief Executive Officer and a member of the board of directors of Schrodinger, Inc. ("Schrodinger") and may be deemed to share voting and dispositive power over the shares held by Schrodinger. The Reporting Person disclaims beneficial ownership of the shares held by Schrodinger. |
| Series B Preferred SharesSEC Table II · derivative / convertible security | IndirectBy Schrodinger, Inc. | 0 |
Reported balance
After 2023-02-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-02-07 · Conversion · Disposed 642,245 · Balance 0 F1: All outstanding Preferred Shares automatically converted into Ordinary Shares immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one Ordinary Share for each one Preferred Share, based on the conversion price currently in effect. The Preferred Shares have no expiration date. F2: The Reporting Person is President, Chief Executive Officer and a member of the board of directors of Schrodinger, Inc. ("Schrodinger") and may be deemed to share voting and dispositive power over the shares held by Schrodinger. The Reporting Person disclaims beneficial ownership of the shares held by Schrodinger. |
| American Depositary SharesSEC Table II · derivative / convertible security | IndirectBy Schrodinger, Inc. | 275,000 |
Reported balance
After 2023-02-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-02-07 · Purchase · Acquired 275,000 · Balance 275,000 F3: Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date. F4: The American Depositary Shares were purchased in the Issuer's initial public offering. F2: The Reporting Person is President, Chief Executive Officer and a member of the board of directors of Schrodinger, Inc. ("Schrodinger") and may be deemed to share voting and dispositive power over the shares held by Schrodinger. The Reporting Person disclaims beneficial ownership of the shares held by Schrodinger. |
Filing footnotes · ownership attribution and instrument terms
F1: All outstanding Preferred Shares automatically converted into Ordinary Shares immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one Ordinary Share for each one Preferred Share, based on the conversion price currently in effect. The Preferred Shares have no expiration date.
F2: The Reporting Person is President, Chief Executive Officer and a member of the board of directors of Schrodinger, Inc. ("Schrodinger") and may be deemed to share voting and dispositive power over the shares held by Schrodinger. The Reporting Person disclaims beneficial ownership of the shares held by Schrodinger.
F3: Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date.
F4: The American Depositary Shares were purchased in the Issuer's initial public offering.
Vir Biotechnology, Inc.
Report date May 27, 2026 · Filed May 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,000 |
Reported balance
After 2026-05-27 transaction · row 1
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 8,000 · Balance 32,000 F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F2: The RSUs will vest in full on May 27, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.10 · Expires 2036-05-26 | Direct | 16,000 |
Reported balance
After 2026-05-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-27 · Grant · Acquired 16,000 · Balance 16,000 F3: The shares subject to the stock option will vest and become exercisable in full on May 27, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
F2: The RSUs will vest in full on May 27, 2027.
F3: The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2026 Filed May 28, 2026 23:24 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $9.10 | $0.00 |
DisclosureSEC source: 0001628280-26-038962 · wk-form4_1780010645.xml · derivative · entry 2 Farid Ramy · CIK 0001797707 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2036-05-26 F3 · shares: The shares subject to the stock option will vest and become exercisable in full on May 27, 2027. Read SEC document |
| May 27, 2026 Filed May 28, 2026 23:24 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-038962 · wk-form4_1780010645.xml · nonDerivative · entry 1 Farid Ramy · CIK 0001797707 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 F1 · kind: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F2 · shares: The RSUs will vest in full on May 27, 2027. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 22:09 UTC | Schrodinger, Inc. SDGR · Entity 4667 | Exercise / conversionStock Option (right to buy) · Derivative | 74,527 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001797707-26-000003 · wk-form4_1776463772.xml · derivative · entry 8 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,527 shares Expires 2026-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on May 11, 2016 and is fully vested. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 22:09 UTC | Schrodinger, Inc. SDGR · Entity 4667 | Exercise / conversionStock Option (right to buy) · Derivative | 43,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001797707-26-000003 · wk-form4_1776463772.xml · derivative · entry 7 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,527 Underlying: Common Stock · 43,000 shares Expires 2026-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2025. F5 · derivative.exercise_date: The option was granted on May 11, 2016 and is fully vested. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 22:09 UTC | Schrodinger, Inc. SDGR · Entity 4667 | Exercise / conversionCommon Stock | 74,527 | $3.07 | $228,797.89 |
DisclosureSEC source: 0001797707-26-000003 · wk-form4_1776463772.xml · nonDerivative · entry 5 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 405,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Includes 132,634 unvested RSUs. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 22:09 UTC | Schrodinger, Inc. SDGR · Entity 4667 | SaleCommon Stock | 43,000 | $12.21 | $524,944.00 |
DisclosureSEC source: 0001797707-26-000003 · wk-form4_1776463772.xml · nonDerivative · entry 4 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 330,824 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.66 to $12.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote(3) of this Form 4. Read SEC document |
| April 17, 2026 Filed Apr 17, 2026 22:09 UTC | Schrodinger, Inc. SDGR · Entity 4667 | Exercise / conversionCommon Stock | 43,000 | $3.07 | $132,010.00 |
DisclosureSEC source: 0001797707-26-000003 · wk-form4_1776463772.xml · nonDerivative · entry 3 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 373,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2025. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 22:09 UTC | Schrodinger, Inc. SDGR · Entity 4667 | Exercise / conversionStock Option (right to buy) · Derivative | 43,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001797707-26-000003 · wk-form4_1776463772.xml · derivative · entry 6 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,527 Underlying: Common Stock · 43,000 shares Expires 2026-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2025. F5 · derivative.exercise_date: The option was granted on May 11, 2016 and is fully vested. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 22:09 UTC | Schrodinger, Inc. SDGR · Entity 4667 | SaleCommon Stock | 43,000 | $12.33 | $530,233.00 |
DisclosureSEC source: 0001797707-26-000003 · wk-form4_1776463772.xml · nonDerivative · entry 2 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 330,824 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.80 to $12.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote(2) of this Form 4. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 22:09 UTC | Schrodinger, Inc. SDGR · Entity 4667 | Exercise / conversionCommon Stock | 43,000 | $3.07 | $132,010.00 |
DisclosureSEC source: 0001797707-26-000003 · wk-form4_1776463772.xml · nonDerivative · entry 1 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 373,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 2, 2025. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 22:28 UTC | Schrodinger, Inc. SDGR · Entity 4667 | SaleCommon Stock | 3,661 | $12.91 | $47,248.87 |
DisclosureSEC source: 0001797707-26-000002 · wk-form4_1772836083.xml · nonDerivative · entry 1 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 330,824 F1 · kind: This sale was effected pursuant to a durable automatic sale instruction under Rule 10b5-1 adopted by the reporting person on March 8, 2023, represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units ("RSUs"). The sale does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.73 to $13.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) of this Form 4. F3 · balance_after: Includes 132,634 unvested RSUs. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:34 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 112,500 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001797707-26-000001 · wk-form4_1772573657.xml · derivative · entry 5 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2036-03-02 F7 · derivative.exercise_date: The option was granted on March 2, 2026. The shares underlying the option are scheduled to vest with respect to 25% of the shares on March 2, 2027 and the remainder are scheduled to vest in equal monthly installments through March 2, 2030, subject to the reporting person's continued service with the company. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:34 UTC | Schrodinger, Inc. SDGR · Entity 4667 | SaleCommon Stock | 5,560 | $11.90 | $66,151.21 |
DisclosureSEC source: 0001797707-26-000001 · wk-form4_1772573657.xml · nonDerivative · entry 4 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 334,485 F4 · kind: This sale was effected pursuant to a durable automatic sale instruction under Rule 10b5-1 adopted by the reporting person on March 8, 2023, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PRSUs. The sale does not represent a discretionary trade by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.69 to $12.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) of this Form 4. F6 · balance_after: Includes an aggregate of 142,009 unvested RSUs. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:34 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantCommon Stock | 48,259 | $0.00 | $0.00 |
DisclosureSEC source: 0001797707-26-000001 · wk-form4_1772573657.xml · nonDerivative · entry 3 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 340,045 F3 · kind: Represents PRSUs previously granted to the reporting person on March 4, 2024, for which the compensation committee of the Issuer's board of directors certified on March 2, 2026 the level of achievement of the performance metrics for the PRSUs. The PRSUs will vest upon the filing of the Issuer's Annual Report on Form 10-K for the year ended December 31, 2026, subject to the reporting person's continued service with the company. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:34 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantCommon Stock | 13,604 | $0.00 | $0.00 |
DisclosureSEC source: 0001797707-26-000001 · wk-form4_1772573657.xml · nonDerivative · entry 2 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 291,786 F2 · kind: Represents the portion of the performance-based restricted stock units ("PRSUs") that were previously granted to the reporting person on February 9, 2023 in connection with the Issuer's annual grant of equity in 2023, that vested on March 2, 2026 following certification by the compensation committee of the Issuer's board of directors of the level of achievement of certain performance metrics for the PRSUs. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:34 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantCommon Stock | 56,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001797707-26-000001 · wk-form4_1772573657.xml · nonDerivative · entry 1 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 278,182 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on March 2, 2026 and will vest in equal installments on each of March 9, 2027, 2028, 2029 and 2030, subject to the reporting person's continued service with the company. Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 23:19 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $4.94 | $0.00 |
DisclosureSEC source: 0001628280-25-028890 · wk-form4_1748906357.xml · derivative · entry 2 Farid Ramy · CIK 0001797707 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2035-05-29 F3 · shares: The shares subject to the stock option will vest and become exercisable in full on May 30, 2026. Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 23:19 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-028890 · wk-form4_1748906357.xml · nonDerivative · entry 1 Farid Ramy · CIK 0001797707 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 F1 · kind: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F2 · shares: The RSUs will vest in full on May 30, 2026. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:28 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $23.36 | $0.00 |
DisclosureSEC source: 0001490978-25-000020 · wk-form4_1741127315.xml · derivative · entry 3 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2035-03-03 F4 · derivative.exercise_date: The option was granted on March 3, 2025. The exercise price per share is equal to 110% of the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant. The shares underlying the option are scheduled to vest with respect to 25% of the shares on March 3, 2026 and the remainder are scheduled to vest in equal monthly installments through March 3, 2029. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:28 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $21.24 | $0.00 |
DisclosureSEC source: 0001490978-25-000020 · wk-form4_1741127315.xml · derivative · entry 2 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2035-03-03 F3 · derivative.exercise_date: The option was granted on March 3, 2025. The shares underlying the option are scheduled to vest with respect to 25% of the shares on March 3, 2026 and the remainder are scheduled to vest in equal monthly installments through March 3, 2029. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:28 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001490978-25-000020 · wk-form4_1741127315.xml · nonDerivative · entry 1 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,932 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs were granted on March 3, 2025 and will vest in equal installments on each of March 4, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continued service with the company. F2 · balance_after: Includes 37,500 unvested RSUs. Read SEC document |
| May 29, 2024 Filed May 31, 2024 18:43 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001628280-24-025999 · wk-form4_1717180989.xml · derivative · entry 3 Farid Ramy · CIK 0001797707 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2034-05-28 F2 · derivative.exercise_date: Shares subject to the stock option vest and become exercisable on the earlier of (i) May 29, 2025, or (i) the date of the Company's next annual meeting of stockholders. Read SEC document |
| May 29, 2024 Filed May 31, 2024 18:43 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001628280-24-025999 · wk-form4_1717180989.xml · derivative · entry 2 Farid Ramy · CIK 0001797707 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2034-05-28 F1 · derivative.exercise_date: 1/3 of the shares subject to the stock option vest and become exercisable on May 29, 2025, and the remaining shares vest in 24 equal monthly installments thereafter. Read SEC document |
| May 29, 2024 Filed May 31, 2024 18:43 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-025999 · wk-form4_1717180989.xml · nonDerivative · entry 1 Farid Ramy · CIK 0001797707 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:49 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 87,271 | $0.00 Strike: $27.76 | $0.00 |
DisclosureSEC source: 0001628280-24-008968 · wk-form4_1709675347.xml · derivative · entry 2 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,271 Underlying: Common Stock · 87,271 shares Expires 2034-03-04 F2 · derivative.exercise_date: The option was granted on March 4, 2024. The exercise price per share is equal to 110% of the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant. The shares underlying the option are scheduled to vest with respect to 25% of the shares on March 4, 2025 and the remainder are scheduled to vest in equal monthly installments through March 4, 2028. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:49 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 126,000 | $0.00 Strike: $25.24 | $0.00 |
DisclosureSEC source: 0001628280-24-008968 · wk-form4_1709675347.xml · derivative · entry 1 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,000 Underlying: Common Stock · 126,000 shares Expires 2034-03-04 F1 · derivative.exercise_date: The option was granted on March 4, 2024. The shares underlying the option are scheduled to vest with respect to 25% of the shares on March 4, 2025 and the remainder are scheduled to vest in equal monthly installments through March 4, 2028. Read SEC document |
| February 09, 2023 Filed Feb 10, 2023 22:00 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 65,525 | $0.00 Strike: $25.62 | $0.00 |
DisclosureSEC source: 0001490978-23-000012 · wf-form4_167606643944365.xml · derivative · entry 2 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,525 Underlying: Common Stock · 65,525 shares Expires 2033-02-09 F2 · derivative.exercise_date: The option was granted on February 9, 2023. The exercise price per share is equal to 110% of the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant. The shares underlying the option are scheduled to vest with respect to 25% of the shares on February 9, 2024 and the remainder are scheduled to vest in equal monthly installments through February 9, 2027. Read SEC document |
| February 09, 2023 Filed Feb 10, 2023 22:00 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 84,960 | $0.00 Strike: $23.29 | $0.00 |
DisclosureSEC source: 0001490978-23-000012 · wf-form4_167606643944365.xml · derivative · entry 1 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,960 Underlying: Common Stock · 84,960 shares Expires 2033-02-09 F1 · derivative.exercise_date: The option was granted on February 9, 2023. The shares underlying the option are scheduled to vest with respect to 25% of the shares on February 9, 2024 and the remainder are scheduled to vest in equal monthly installments through February 9, 2027. Read SEC document |
| February 07, 2023 Filed Feb 10, 2023 00:09 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | PurchaseAmerican Depositary Shares · Derivative | 275,000 | $15.00 | $4,125,000.00 |
DisclosureSEC source: 0001209191-23-008166 · doc4.xml · derivative · entry 3 Farid Ramy · CIK 0001797707 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Schrodinger, Inc. Disclosed balance after: 275,000 Underlying: Ordinary Shares · 825,000 shares Expires not disclosed F3 · derivative.exercise_price: Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date. F4 · kind: The American Depositary Shares were purchased in the Issuer's initial public offering. F3 · derivative.exercise_date: Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date. F3 · derivative.expiration_date: Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date. F2 · ownership.nature: The Reporting Person is President, Chief Executive Officer and a member of the board of directors of Schrodinger, Inc. ("Schrodinger") and may be deemed to share voting and dispositive power over the shares held by Schrodinger. The Reporting Person disclaims beneficial ownership of the shares held by Schrodinger. Read SEC document |
| February 07, 2023 Filed Feb 10, 2023 00:09 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | ConversionSeries B Preferred Shares · Derivative | 642,245 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-008166 · doc4.xml · derivative · entry 2 Farid Ramy · CIK 0001797707 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Schrodinger, Inc. Disclosed balance after: 0 Underlying: Ordinary Shares · 642,245 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All outstanding Preferred Shares automatically converted into Ordinary Shares immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one Ordinary Share for each one Preferred Share, based on the conversion price currently in effect. The Preferred Shares have no expiration date. F1 · price: All outstanding Preferred Shares automatically converted into Ordinary Shares immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one Ordinary Share for each one Preferred Share, based on the conversion price currently in effect. The Preferred Shares have no expiration date. F1 · derivative.exercise_date: All outstanding Preferred Shares automatically converted into Ordinary Shares immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one Ordinary Share for each one Preferred Share, based on the conversion price currently in effect. The Preferred Shares have no expiration date. F1 · derivative.expiration_date: All outstanding Preferred Shares automatically converted into Ordinary Shares immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one Ordinary Share for each one Preferred Share, based on the conversion price currently in effect. The Preferred Shares have no expiration date. F2 · ownership.nature: The Reporting Person is President, Chief Executive Officer and a member of the board of directors of Schrodinger, Inc. ("Schrodinger") and may be deemed to share voting and dispositive power over the shares held by Schrodinger. The Reporting Person disclaims beneficial ownership of the shares held by Schrodinger. Read SEC document |
| February 07, 2023 Filed Feb 10, 2023 00:09 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | ConversionOrdinary Shares | 642,245 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-008166 · doc4.xml · nonDerivative · entry 1 Farid Ramy · CIK 0001797707 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Schrodinger, Inc. Disclosed balance after: 3,260,495 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All outstanding Preferred Shares automatically converted into Ordinary Shares immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one Ordinary Share for each one Preferred Share, based on the conversion price currently in effect. The Preferred Shares have no expiration date. F2 · ownership.nature: The Reporting Person is President, Chief Executive Officer and a member of the board of directors of Schrodinger, Inc. ("Schrodinger") and may be deemed to share voting and dispositive power over the shares held by Schrodinger. The Reporting Person disclaims beneficial ownership of the shares held by Schrodinger. Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 21:46 UTC | Schrodinger, Inc. SDGR · Entity 4667 | Exercise / conversionStock Option (right to buy) · Derivative | 66,886 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001490978-23-000002 · wf-form4_167295515936956.xml · derivative · entry 3 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,886 shares Expires 2023-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2022. F3 · derivative.exercise_date: The option was granted on January 8, 2013 and is fully vested. Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 21:46 UTC | Schrodinger, Inc. SDGR · Entity 4667 | SaleCommon Stock | 66,886 | $18.28 | $1,222,669.39 |
DisclosureSEC source: 0001490978-23-000002 · wf-form4_167295515936956.xml · nonDerivative · entry 2 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,432 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.04 to $18.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote(2) of this form 4. Read SEC document |
| January 04, 2023 Filed Jan 5, 2023 21:46 UTC | Schrodinger, Inc. SDGR · Entity 4667 | Exercise / conversionCommon Stock | 66,886 | $1.20 | $80,263.20 |
DisclosureSEC source: 0001490978-23-000002 · wf-form4_167295515936956.xml · nonDerivative · entry 1 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,318 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8, 2022. Read SEC document |
| February 09, 2022 Filed Feb 10, 2022 02:13 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 215,000 | $0.00 Strike: $27.76 | $0.00 |
DisclosureSEC source: 0001209191-22-008271 · doc4.xml · derivative · entry 1 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 215,000 shares Expires 2032-02-09 F1 · derivative.exercise_date: The option was granted on February 9, 2022. The shares underlying the option are scheduled to vest with respect to 25% of the shares on February 9, 2023 and the remainder are scheduled to vest in equal monthly installments through February 9, 2026. Read SEC document |
| February 27, 2021 Filed Mar 2, 2021 21:38 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $102.48 | $0.00 |
DisclosureSEC source: 0001209191-21-016052 · doc4.xml · derivative · entry 1 Farid Ramy · CIK 0001797707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-02-27 F1 · derivative.exercise_date: The option was granted on February 27, 2021. The shares underlying the option are scheduled to vest with respect to 25% of the shares on February 27, 2022 and the remainder are scheduled to vest in equal monthly installments through February 27, 2025. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:25 UTC | Schrodinger, Inc. SDGR · Entity 4667 | SaleCommon Stock | 10,151 | $53.61 | $544,144.36 |
DisclosureSEC source: 0000899243-20-025720 · doc4.xml · nonDerivative · entry 2 Farid Ramy · CIK 0001797707 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,432 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.32 to $54.05, inclusive. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:25 UTC | Schrodinger, Inc. SDGR · Entity 4667 | SaleCommon Stock | 9,849 | $52.81 | $520,159.18 |
DisclosureSEC source: 0000899243-20-025720 · doc4.xml · nonDerivative · entry 1 Farid Ramy · CIK 0001797707 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,583 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.31 to $53.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 20:37 UTC | Schrodinger, Inc. SDGR · Entity 4667 | SaleCommon Stock | 15,429 | $71.49 | $1,103,000.70 |
DisclosureSEC source: 0000899243-20-022418 · doc4.xml · nonDerivative · entry 8 Farid Ramy · CIK 0001797707 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,432 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2020. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.29 to $71.98, inclusive. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 20:37 UTC | Schrodinger, Inc. SDGR · Entity 4667 | SaleCommon Stock | 15,767 | $70.62 | $1,113,509.69 |
DisclosureSEC source: 0000899243-20-022418 · doc4.xml · nonDerivative · entry 7 Farid Ramy · CIK 0001797707 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,861 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2020. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.26 to $71.19, inclusive. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 20:37 UTC | Schrodinger, Inc. SDGR · Entity 4667 | SaleCommon Stock | 18,804 | $69.83 | $1,313,017.51 |
DisclosureSEC source: 0000899243-20-022418 · doc4.xml · nonDerivative · entry 6 Farid Ramy · CIK 0001797707 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,628 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.25 to $70.235, inclusive. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:37 UTC | Schrodinger, Inc. SDGR · Entity 4667 | SaleCommon Stock | 4,950 | $68.54 | $339,281.42 |
DisclosureSEC source: 0000899243-20-022418 · doc4.xml · nonDerivative · entry 5 Farid Ramy · CIK 0001797707 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,432 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.38 to $68.78, inclusive. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:37 UTC | Schrodinger, Inc. SDGR · Entity 4667 | SaleCommon Stock | 36,203 | $67.72 | $2,451,786.63 |
DisclosureSEC source: 0000899243-20-022418 · doc4.xml · nonDerivative · entry 4 Farid Ramy · CIK 0001797707 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,382 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.38 to $68.35, inclusive. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:37 UTC | Schrodinger, Inc. SDGR · Entity 4667 | SaleCommon Stock | 34,416 | $66.92 | $2,303,043.00 |
DisclosureSEC source: 0000899243-20-022418 · doc4.xml · nonDerivative · entry 3 Farid Ramy · CIK 0001797707 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,585 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.38 to $67.37, inclusive. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:37 UTC | Schrodinger, Inc. SDGR · Entity 4667 | SaleCommon Stock | 3,431 | $66.01 | $226,481.34 |
DisclosureSEC source: 0000899243-20-022418 · doc4.xml · nonDerivative · entry 2 Farid Ramy · CIK 0001797707 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,001 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.37 to $66.35, inclusive. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:37 UTC | Schrodinger, Inc. SDGR · Entity 4667 | SaleCommon Stock | 1,000 | $64.87 | $64,874.00 |
DisclosureSEC source: 0000899243-20-022418 · doc4.xml · nonDerivative · entry 1 Farid Ramy · CIK 0001797707 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,432 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.36 to $65.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (9) of this Form 4. Read SEC document |
| February 10, 2020 Filed Feb 10, 2020 21:08 UTC | Schrodinger, Inc. SDGR · Entity 4667 | GrantStock Option (right to buy) · Derivative | 896,280 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-003798 · doc4.xml · derivative · entry 1 Farid Ramy · CIK 0001797707 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 896,280 Underlying: Common Stock · 896,280 shares Expires 2030-02-04 F1 · derivative.exercise_date: The option was granted on February 5, 2020. The commencement of vesting was contingent upon the closing of the Issuer's initial public offering, which occurred on February 10, 2020. The shares underlying the option are scheduled to vest with respect to 25% of the shares on February 5, 2021 and the remainder are scheduled to vest in equal monthly installments through February 5, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.